3 Reasons This Marijuana Stock Could Be Ready to Rebound — and 1 Reason It Won't


Could the worst be over for Insys Therapeutics NASDAQ INSY The cannabinoid focused biotech has been singing the blues for quite a while Government investigations into its sales and marketing practices plunging sales for its top product and a major pipeline setback just a